CVS Dropping Zepbound: What It Means For Patients, Payers, And …
May 5, 2025 · CVS Caremark’s decision may be an attempt to slow Eli Lilly’s growth and influence. Lilly already has an oral GLP-1 drug in the pipeline, and another type that is …
Lilly star weight-loss drug Zepbound faces coverage challenge from CVS …
Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival …
Zepbound Access | Zepbound (tirzepatide)
Important Updates on Zepbound ® Coverage with CVS Caremark ... Zepbound ® and its delivery device base and LillyDirect ® are registered trademarks owned or licensed by Eli Lilly and …
CVS Health Announces It Will Drop Zepbound and Prioritize …
6 days ago · CVS Health's formulary change highlights competitive dynamics between PBMs and pharmaceutical companies, impacting patient access to weight management drugs. ... Eli Lilly …
CVS drops Zepbound from preferred coverage in blow to Eli Lilly
May 1, 2025 · CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor of Novo Nordisk A/S's Wegovy for weight loss — a major blow to the …
Eli Lilly’s Shares Sink on Investor Concerns About CVS Move - MSN
Eli Lilly & Co.’s shares saw the biggest one-day drop since 2008 after CVS Health Corp. announced a plan to drop its blockbuster weight-loss drug Zepbound from its preferred list, …
Novo's Wegovy secures preferred obesity spot on CVS formulary
May 1, 2025 · Novo has locked in a formulary deal with CVS that could give its star weight loss drug Wegovy a major advantage over its Eli Lilly rival Zepbound.
Lilly Star Weight-Loss Drug Zepbound Faces Coverage Challenge From CVS ...
May 1, 2025 · Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda …
Eli Lilly downplays CVS move to drop Zepbound coverage, shares …
May 1, 2025 · Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of …
CVS Health favors Novo’s Wegovy in a blow for Lilly (LLY)
May 1, 2025 · Eli Lilly (NYSE: LLY) shares dropped on Thursday after lowering its full-year outlook amid a decision by CVS Health (NYSE: CVS) to limit access to the company’s popular …
- Some results have been removed